Fluoromedroxyprogesterone acetate: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
No edit summary |
||
| Line 86: | Line 86: | ||
{{Antineoplastic-drug-stub}} | {{Antineoplastic-drug-stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
<gallery> | <gallery> | ||
File:Fluoromedroxyprogesterone_acetate.svg|Fluoromedroxyprogesterone acetate | File:Fluoromedroxyprogesterone_acetate.svg|Fluoromedroxyprogesterone acetate | ||
</gallery> | </gallery> | ||
Revision as of 21:55, 16 March 2025
Fluoromedroxyprogesterone acetate (FMPA, 9α-fluoromedroxyprogesterone acetate, or 9α-FMPA) is a synthetic steroid medication which was under development by Meiji Dairies Corporation in the 1990s and 2000s for the potential treatment of cancers but was never marketed.<ref name="AdisInsight">https://adisinsight.springer.com/drugs/800011224</ref><ref name="pmid9118456">,
Synthesis of a new potent anti-angiogenic agent, 17 alpha-acetoxy-9 alpha-fluoro-6 alpha-methylprogesterone (9 alpha-fluoromedroxyprogesterone acetate [FMPA]), Chem. Pharm. Bull., Vol. 45(Issue: 2), pp. 421–3, DOI: 10.1002/chin.199737217, PMID: 9118456,</ref><ref name="pmid10701698">, Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate, Biopharm Drug Dispos, Vol. 20(Issue: 6), pp. 277–84, DOI: <277::AID-BDD186>3.0.CO;2-T 10.1002/(SICI)1099-081X(199909)20:6<277::AID-BDD186>3.0.CO;2-T, PMID: 10701698,</ref><ref name="pmid10530777">, Anti-angiogenic activity of a novel synthetic agent, 9alpha-fluoromedroxyprogesterone acetate, Cancer Lett., Vol. 145(Issue: 1-2), pp. 107–14, DOI: 10.1016/S0304-3835(99)00239-6, PMID: 10530777,</ref><ref name="pmid10799740">, Inhibition by 9alpha-fluoromedoroxyprogesterone acetate (FMPA) against mammary carcinoma induced by dimethylbenz[a]anthracene in rats and angiogenesis in the rabbit cornea - comparison with medroxyprogesterone acetate (MPA), Cancer Lett., Vol. 154(Issue: 1), pp. 63–9, DOI: 10.1016/S0304-3835(00)00375-X, PMID: 10799740,</ref><ref name="pmid17077554">, Synthesis and anti-tumor activity of a fluorinated analog of medroxyprogesterone acetate (MPA), 9alpha-fluoromedroxyprogesterone acetate (FMPA), Chem. Pharm. Bull., Vol. 54(Issue: 11), pp. 1567–70, DOI: 10.1248/cpb.54.1567, PMID: 17077554,</ref><ref name="pmid17142973">, Suppression of laser-induced choroidal neovascularization by subconjunctival injection of 9alpha-fluoromedroxyprogesterone acetate (FMPA), an anti-angiogenic agent, in rats, Biol. Pharm. Bull., Vol. 29(Issue: 12), pp. 2410–4, DOI: 10.1248/bpb.29.2410, PMID: 17142973,</ref> It is described as an antiangiogenic agent, with about two orders of magnitude greater potency for inhibition of angiogenesis than its parent compound medroxyprogesterone acetate.<ref name="pmid9118456" /><ref name="pmid10530777" /><ref name="pmid10799740" /> FMPA showed about the same affinities for the progesterone and glucocorticoid receptors as MPA.<ref name="pmid10530777" /> It reached the preclinical phase of research prior to the discontinuation of its development.<ref name="AdisInsight" />
See also
References
<references group="" responsive="1"></references>
External links
| Glucocorticoid receptor modulators | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|




